Ventodep ER (extended-release) is a next-generation bronchodilator engineered for the long-term management of moderate to severe chronic obstructive pulmonary disease (COPD) and asthma. Utilizing a proprietary matrix delivery system, it ensures consistent therapeutic plasma levels over 24 hours, significantly reducing the frequency of rescue inhaler use. This formulation is designed to enhance patient adherence and provide predictable, around-the-clock symptom control, making it a cornerstone in modern pulmonary maintenance therapy. Clinical studies demonstrate superior efficacy in improving forced expiratory volume (FEV1) and exercise tolerance compared to conventional short-acting agents.

Features

• Extended-release formulation for 24-hour bronchodilation
• Active ingredient: Salmeterol Xinafoate 50mcg per dose
• Proprietary controlled-release matrix technology
• Metered-dose inhaler (MDI) with dose counter
• Compatible with common spacer devices
• Temperature-stable between 15°–30°C (59°–86°F)
• 120 actuations per canister
• Preservative-free formulation
• Child-resistant safety cap

Benefits

• Provides sustained bronchodilation, reducing daytime and nocturnal symptom breakthrough
• Decreases frequency of acute exacerbations and hospitalizations
• Enhances overall quality of life through improved exercise capacity and sleep quality
• Simplifies dosing regimen to once-daily administration, supporting long-term adherence
• Minimizes systemic side effects through targeted pulmonary delivery
• Reduces dependency on short-acting beta-agonists (SABAs)

Common use

Ventodep ER is indicated for the maintenance treatment of bronchoconstriction in patients with chronic obstructive pulmonary disease (COPD), including emphysema and chronic bronchitis, and as a prophylactic agent in asthma management. It is not intended for immediate relief of acute bronchospasm. It is commonly prescribed for adults and adolescents aged 12 years and older who require continuous bronchodilator therapy to maintain airway patency and prevent symptom recurrence.

Dosage and direction

The recommended dosage for Ventodep ER is one inhalation (50mcg) once daily, preferably at the same time each day. Shake the inhaler well before each use. Prime the inhaler before first use or if not used for more than 7 days by releasing 4 test sprays into the air away from the face. Exhale fully away from the mouthpiece, place lips firmly around it, and inhale deeply and slowly while pressing down firmly on the canister. Hold breath for 10 seconds, then exhale slowly. Wait 1 minute before administering a second inhalation if prescribed. Do not exceed the recommended dose.

Precautions

• Not for use in acute bronchospasm; always keep a fast-acting rescue inhaler available.
• Use with caution in patients with cardiovascular disorders (e.g., hypertension, arrhythmia, coronary artery disease).
• May cause paradoxical bronchospasm; discontinue immediately if it occurs.
• Be aware of potential hypokalemia or hyperglycemia, especially in diabetic patients.
• Not recommended during pregnancy unless clearly needed; discuss risks with a healthcare provider.
• Avoid use in patients with a history of hypersensitivity to sympathomimetic amines.
• Monitor for signs of worsening asthma or COPD, such as increased shortness of breath or peak flow variability.

Contraindications

• Hypersensitivity to salmeterol or any component of the formulation.
• Treatment of status asthmaticus or other acute episodes of COPD where intensive measures are required.
• Use as a monotherapy in asthma without an inhaled corticosteroid (per current GINA guidelines).
• Severe cardiovascular instability including tachyarrhythmias.

Possible side effect

Common (≥1/100):

• Headache
• Tremor
• Palpitations
• Throat irritation
• Cough

Uncommon (≥1/1000):

• Tachycardia
• Muscle cramps
• Dizziness
• Nausea

Rare (<1/1000):

• Paradoxical bronchospasm
• Hypersensitivity reactions (urticaria, rash, angioedema)
• Atrial fibrillation
• Hyperglycemia

Drug interaction

• Beta-blockers (e.g., propranolol) may antagonize bronchodilator effects.
• Concomitant use with other sympathomimetic agents may increase cardiovascular side effects.
• Diuretics or corticosteroids may exacerbate hypokalemia.
• MAO inhibitors or tricyclic antidepressants may potentiate vascular effects.
• QT-prolonging agents (e.g., erythromycin) may increase risk of arrhythmias.

Missed dose

If a dose is missed, take it as soon as remembered unless it is nearly time for the next dose. Do not double the dose to make up for a missed one. Resume the regular dosing schedule. Inform your healthcare provider if multiple doses are missed, as symptom control may be compromised.

Overdose

Overdosage may lead to exaggerated pharmacologic effects such as tachycardia, tremor, hypertension, hypokalemia, and angina. Symptomatic treatment is recommended; cardioselective beta-blockers may be used with caution in patients without bronchospastic disease. Provide supportive care, including monitoring of electrolytes and cardiac function. Seek immediate medical attention.

Storage

Store at room temperature (15°–30°C or 59°–86°F). Do not freeze or expose to direct sunlight. Keep the canister away from open flame or heat sources; it may burst if incinerated. Store with the mouthpiece down. Keep out of reach of children and pets. Discard 3 months after removal from foil pouch or when the dose counter reads “0”.

Disclaimer

Ventodep ER is a prescription medication and should be used only under the supervision of a qualified healthcare professional. This information is not exhaustive; refer to the full prescribing information for complete details. Individual response may vary. Not all uses or interactions are listed here. Always follow your provider’s instructions and report any adverse effects promptly.

Reviews

“After switching to Ventodep ER, my nighttime symptoms have virtually disappeared. I no longer wake up gasping, and my rescue inhaler use has dropped from daily to maybe once a month.” — Maria K., diagnosed with COPD (4.7/5)

“As a pulmonologist, I’ve observed marked improvement in adherence and FEV1 stability in my patients on Ventodep ER. The once-daily dosing is a significant advantage over bid regimens.” — Dr. Evan R., MD (4.8/5)

“I was skeptical about another inhaler, but the extended relief is real. I can finally take my dog for longer walks without worrying about shortness of breath.” — James L., asthma patient (4.5/5)